Caladrius Biosciences (CLBS) Financials

$4.23

$-0.31 (-6.83%)

As on 13-Oct-2022 09:30EDT

Market cap

$26 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

0.2

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Operating Revenue	--	--	--	--	--	--
Cost of Revenue	--	--	--	--	7.50	2.70
Gross Profit	--	--	--	--	-7.50	-2.70
Operating Expenses	27.16	29.05	19.15	20.09	16.99	27.59
Operating Profit (EBIT)	-27.16	-29.05	-19.15	-20.09	-16.99	-27.59
Other Income	--	--	0.13	0.74	0.82	0.27
Profit before Tax	-27.05	-28.97	-19.01	-19.35	-16.17	-27.70
Provision for Tax	-2.48	-1.51	-10.87	--	--	-11.53
Profit after Tax (Net Income)	-24.57	-27.47	-8.15	-19.36	-16.17	22.98
Minority Interest	--	--	0.01	0.01	-0.27	-0.18
Consolidated Profit	-24.57	-27.47	-8.15	-19.36	-16.17	22.98

Liabilities ($ Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Shareholder's Funds	82.39	92.00	32.50	20.82	37.73	50.51
Minority Interest	--	--	-0.25	-0.26	-0.27	-0.32
Non-Current Liabilities	0.38	0.49	0.25	0.62	1.51	3.87
Current Liabilities	3.36	4.52	3.51	5.98	5.62	9.31
Total Liabilities	89.49	97.01	36.00	27.15	44.58	63.38

Assets ($ Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Non-Current Assets	10.93	0.83	0.67	1.18	0.47	2.27
Current Assets	74.95	94.97	35.33	25.97	44.11	61.11
Total Assets	89.23	97.01	36.26	27.42	44.85	63.69
Total Debt*	0.56	--	0.62	0.35	--	0.16
Net Current Assets	71.59	91.66	31.83	20.00	38.49	51.80

Cashflow ($ Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Cash From Operating Activities	--	-22.25	-8.82	-18.88	-19.99	-20.88
Cash Flow from Investing Activities	--	-54.90	-7.28	21.43	-4.71	41.27
Cash from Financing Activities	--	85.28	18.58	1.18	0.82	-0.93
Net Cash Inflow / Outflow	--	--	2.48	3.73	-23.87	19.46

Financials Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Adjusted EPS ($)	--	--	--	--	--	--
Cash EPS ($)	--	--	--	--	--	--
Adjusted Book Value ($)	--	--	--	--	--	--
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	--	--	--	--	--
Free Cash Flow per Share ($)	--	--	--	--	--	--

Profitability Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
ROCE (%)	--	-43.90	-30.02	-65.75	-36.58	73.72
ROE (%)	-28.18	-44.12	-30.57	-66.14	-36.65	82.97
ROA (%)	-24.37	-41.30	-25.81	-53.98	-29.95	39.89
EBIT Margin (%)	--	--	--	--	--	--
Net Margin (%)	--	--	-6,174.24	-2,616.35	-1,962.01	8,413.99
Cash Profit Margin (%)	--	--	--	--	--	--

Growth Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Revenue Growth (%)	--	--	--	--	--	-1.00
EBIT Growth (%)	21.43	-51.34	4.71	-18.28	38.44	10.00
Net Profit Growth (%)	1.75	-237.01	57.91	-19.76	-170.36	170.37
EPS Growth (%)	--	--	--	--	--	--
Book Value Growth (%)	--	--	--	--	--	--

Valuation Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Price / Earnings	--	--	--	--	--	--
Price / Book Value	0.25	--	--	--	--	--
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	1.93	3.29	1.78	1.24	2.57	2.02
Close Price ($)	0.53	0.84	1.43	2.51	3.56	3.51
High Price ($)	1.60	4.89	3.64	5.44	11.65	7.79
Low Price ($)	0.40	0.81	1.05	2.00	3.05	2.63
Market Cap ($ Cr)	25.83	--	--	--	--	--

Solvency Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Debt to Equity	--	--	0.02	0.02	--	0.00
Short term debt to equity ratio	0.00	--	0.01	0.02	--	0.00
Current Ratio	22.33	21.00	10.08	4.35	7.85	6.56
Quick Ratio	22.33	--	--	--	--	6.56
Interest Coverage	--	--	--	--	-3,397.40	-73.04

Operating Efficiency Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Debtors to sales (%)	--	--	--	--	--	--
Asset Turnover	--	--	--	--	--	--
Receivable days	--	--	--	--	--	--
Inventory Days	--	--	--	--	--	242.28
Payable days	--	--	--	--	51.26	386.21
Cash Conversion Cycle	--	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.